Compare Amylx Pharmaceuticals Inc (AMLX) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $505.73M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 5.2× Ginkgo Bioworks Holdings Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | DNA | |
|---|---|---|
Market Cap | $2.64B | $505.73M |
Sector | Health | Health |
52-Week High | $24.19 | $16.14 |
52-Week Low | $7.82 | $5.48 |
Enterprise Value | $2.39B | $607.68M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
